Oruka Therapeutics (NASDAQ:ORKA) SVP Arjun Agarwal Sells 1,587 Shares

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 1,587 shares of the company’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $80.95, for a total value of $128,467.65. Following the completion of the sale, the senior vice president owned 15,312 shares in the company, valued at $1,239,506.40. This represents a 9.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arjun Agarwal also recently made the following trade(s):

• On Monday, June 15th, Arjun Agarwal sold 395 shares of Oruka Therapeutics stock. The shares were sold at an average price of $69.69, for a total transaction of $27,527.55.
• On Friday, June 12th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The shares were sold at an average price of $69.72, for a total transaction of $659,481.48.
• On Monday, May 18th, Arjun Agarwal sold 10,290 shares of Oruka Therapeutics stock. The shares were sold at an average price of $59.07, for a total transaction of $607,830.30.

Oruka Therapeutics Stock Performance

Shares of ORKA opened at $85.38 on Tuesday. Oruka Therapeutics, Inc. has a 1 year low of $10.77 and a 1 year high of $91.00. The company’s 50 day simple moving average is $65.16 and its 200 day simple moving average is $45.89. The company has a market capitalization of $5.15 billion, a price-to-earnings ratio of -44.01 and a beta of -0.25.

Oruka Therapeutics (NASDAQ:ORKA) last released its earnings results on Wednesday, May 13th. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.04. Equities analysts expect that Oruka Therapeutics, Inc. will post -2.06 EPS for the current fiscal year.

Institutional Trading of Oruka Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of ORKA. Royal Bank of Canada lifted its position in Oruka Therapeutics by 47.2% during the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after buying an additional 365 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in shares of Oruka Therapeutics in the fourth quarter worth $37,000. PNC Financial Services Group Inc. purchased a new position in shares of Oruka Therapeutics in the 3rd quarter valued at $39,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Oruka Therapeutics in the 4th quarter valued at $67,000. Finally, Russell Investments Group Ltd. acquired a new position in shares of Oruka Therapeutics during the 3rd quarter valued at $43,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on ORKA shares. Leerink Partners set a $120.00 target price on Oruka Therapeutics in a research report on Thursday, April 30th. Stifel Nicolaus upped their price objective on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the company a “buy” rating in a research note on Friday, March 13th. BTIG Research reiterated a “buy” rating and set a $151.00 price objective on shares of Oruka Therapeutics in a report on Thursday, May 14th. HC Wainwright reissued a “buy” rating on shares of Oruka Therapeutics in a research report on Wednesday, June 3rd. Finally, Barclays boosted their target price on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the company an “overweight” rating in a report on Monday, April 27th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $131.30.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.